Rigel Pharmaceuticals prelim Q4 revenue beats estimates

Overview

• Biotechnology firm's preliminary Q4 revenue beats analyst expectations

• Net product sales for Q4 expected to be $65.4 million, grew compared to the same period last year

• Company anticipates positive net income for full year 2026

Outlook

• Rigel anticipates 2026 total revenue of $275 to $290 mln

• Company expects net product sales of $255 to $265 mln in 2026

Result Drivers

• PRODUCT SALES GROWTH - Rigel reported net product sales of $65.4 mln for Q4 2025, up from $46.5 mln in Q4 2024, driven by increased sales of TAVALISSE, GAVRETO, and REZLIDHIA

• CONTRACT REVENUE CONTRIBUTION - Q4 2025 contract revenues were $4.4 mln, including collaborations with Grifols, Kissei, and Medison Pharma

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $46.00, about 12.6% above its January 9 closing price of $40.84

• The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release: ID:nPn9HwhFca

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.